The document was uncovered by the Los Angeles law firm, Baul and Hedlund, which alleges Glaxo downplayed the risks of the drug, including increased suicidal behavior in young adults.
The April 2000 memo states that the program aimed to "strengthen the product positioning and overcome competitive issues," facing Paxil.
A spokeswoman for the British drugmaker had no immediate comment Wednesday afternoon.
Get Action News on your website
